Tarceva PFS data much better than chemo in NSCLC
This article was originally published in Scrip
Roche’s EGFR targeted drug Tarceva (erlotinib) nearly tripled progression-free survival (PFS) compared with standard chemotherapy in its first prospective Phase III trial in newly diagnosed, advanced non-small cell lung cancer (NSCLC) patients whose tumours carry EGFR activating mutations. The results were presented at the ESMO meeting in Milan, Italy.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.